Submitted: 17 Jun 2020
Accepted: 30 Aug 2020
ePublished: 09 Sep 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2021;10(2): e13.
doi: 10.34172/npj.2021.13

Scopus ID: 85111442746
  Abstract View: 8755
  PDF Download: 3526


Metformin induced acute kidney injury; a systematic review

Mahnaz Momenzadeh 1* ORCID logo, Bhaskar VKS Lakkakula 2 ORCID logo

1 Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur, India
*Corresponding Author: *Corresponding author: Mahnaz Momenzadeh, Email:, Email: mahnazmomenzadehf@gmail.com


Introduction: Metformin is the best proven first-line treatment for type 2 diabetes (T2DM), based on both national and international guidelines. The present systematic review is aimed to examine the acute kidney injury (AKI) risk associated with metformin.

Methods: A systematic literature search was performed in MEDLINE, PubMed and google scholar, to retrieve the literature related to the metformin use. A bibliographic management software (Endnote X9) was used for managing the literature. The following keywords were used: “Acute renal injury OR ARI”, “Acute kidney injury OR AKI”,” Metformin”, “ Type 2 diabetes mellitus OR T2DM”, “Diabetic patients”, “Renal function”, “CKD”.

Results: About 28 relevant articles were found during the electronic and manual search. Finally, a total of four articles that fulfill the inclusion criteria were used for this systematic literature review. There is no evidence to suggest that metformin increases the incidence of AKI and is associated with an increased survival of 28 days following AKI event. Further, there was no difference in the incidence of AKI in patients who continued metformin after arterial contrast exposure compared with the control group.

Conclusion: In summary, there is no evidence that metformin increases the incidence of AKI. More clinical trials are needed in this area, to investigate more evidence so that we can better understand the outcome.

Implication for health policy/practice/research/medical education:

There is no evidence that metformin increases incidence of acute kidney injury.

Please cite this paper as: Momenzadeh M, Lakkakula BVKS. Metformin induced acute kidney injury; a systematic review. J Nephropharmacol. 2021;10(2):e13. DOI: 10.34172/npj.2021.13.

First Name
Last Name
Email Address
Security code

Abstract View: 8756

Your browser does not support the canvas element.

PDF Download: 3526

Your browser does not support the canvas element.